Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      15829708200; 56328294100; 7202860969; 7003855087; 7004374085; 465624; 3955607; 4381521; 802813; 591076; WOS:Henriquez-Hernandez, LA; WOS:Moreno, M; WOS:Rey, A; WOS:Lloret, M; WOS:Lara, PC
    • Publication Date:
      2012
    • Collection:
      Universidad de Las Palmas de Gran Canaria: Acceda
    • Abstract:
      Objective: To explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients. Subjects and Methods: 131 consecutive patients suffering from oral cavity squamous cell carcinoma were included in the study. In the whole series, the mean follow-up for survivors was 123.11 ± 40.36 months. Patients in tumour stages I and II were referred to surgery; patients in stage III-IV to postoperative radiotherapy (mean dose = 62.13 ± 7.74 Gy in 1.8–2 Gy/fraction). MVP expression was studied by immunohistochemistry in paraffin-embedded tumour tissue. Results: MVP expression was positive in 112 patients (85.5%) and no relation was found with clinic pathological variables. MVP overexpression (those tumours with moderate or strong expression of the protein) was related to insulin-like growth factor receptor-1 (IGF-1R) expression (P = 0.014). Tumour stage of the disease was the most important prognostic factor related to survival. Tumours overexpressing MVP and IGF-1R were strongly related to poor disease-free survival (P = 0.008, Exp(B) = 2.730, CI95% (1.302-5.724)) and cause-specific survival (P = 0.014, Exp(B) = 2.570, CI95% (1.215-5.437)) in patients achieving tumour stages III-IV, in multivariate analysis. Conclusions: MVP and IGF-1R expression were related in oral squamous cell carcinoma and conferred reduced long-term survival in patients suffering from advanced stages of the disease. ; Peer Reviewed ; 1,04 ; 2,107 ; Q1 ; Q2 ; SCIE
    • Relation:
      Radiation Oncology; Scopus; http://hdl.handle.net/10553/8999; 000311416700001; Sí
    • Accession Number:
      10.1186/1748-717X-7-147
    • Online Access:
      http://hdl.handle.net/10553/8999
      https://doi.org/10.1186/1748-717X-7-147
    • Rights:
      Luis Henríquez-Hernández et al.; licensee BioMed Central Ltd. ; info:eu-repo/semantics/openAccess
    • Accession Number:
      edsbas.DF325730